CAPE (Caffeic Acid Phenethyl Ester)-based Propolis Extract (Bio 30) Suppresses the Growth of Human Neurofibromatosis (NF) Tumor Xenografts in Mice

M. Demestre1, S. M. Messeri2, N. Celli2, M. Shahhossini2, L. Kluwe1, V. Mautner1 and H. Maruta1*

1UKE (Universitaets Klinikum Eppendorf), Hamburg 20246, Germany
2MBL (Marine Biological Laboratory), Woods Hole, MA 02543, USA
3Consorzio Mario Negri Sud, Via Nazionale, Chieti 66030, Italy

INTRODUCTION

Propolis from bee hives (also called ‘bee wax’) contains a 100 million years of wisdom of bee colonies protecting their larva from a variety of diseases. Propolis has been used since ancient Egypt times as a traditional/folk medicine for the treatment of infection, wound and inflammation as well as for preparing mummies. Entering our modern era, propolis was first identified as an anticancer remedy in the late 1980s when Dezider Grunberger’s group at Columbia University found that CAPE (caffeic acid phenethyl ester) was the major anticancer ingredient in a propolis sample from Israel (Grunberger et al., 1988). CAPE is a derivative of caffeic acid (CA) that down-regulates the GTPase Rac, a direct activator of the kinase PAK1 (Xu et al., 2005). As a consequence, CAPE eventually inactivates PAK1. Interestingly, a propolis from New Zealand (NZ) reportedly showed the highest CAPE content (6–7% of extract) of a variety of propolis samples from around the world, whereas Brazilian green propolis contains another anticancer ingredient called ARC (artepillin C), instead of CAPE, which also inactivates PAK1 (Maruta and Ohta, 2008).

Recently we and others have shown that more than 70% of human cancers and all NF (neurofibromatosis) tumors are highly dependent on PAK1 for their growth, but not normal cells (Sasakawa et al., 2003; Hirokawa et al., 2004, 2005a, 2005b; Maruta and Ohta, 2008). Dysfunction of the NFI gene coding a RAS GAP is the major cause of type 1 NF, whereas type 2 NF is caused primarily by dysfunction of the NF2 gene product called merlin that inhibits directly PAK1, an oncogenic Rac/CDC42-dependent Ser/Thr kinase. It was demonstrated previously that PAK1 is essential for the growth of both NF1 and NF2 tumors. Thus, several anti-PAK1 drugs, including FK228 and CEP-1347, are being developed for the treatment of NF tumors. However, so far no effective NF therapeutic is available on the market. Since propolis, a very safe healthcare product from bee hives, contains anticancer ingredients called CAPE (caffeic acid phenethyl ester) or ARC (artepillin C), depending on the source, several anti-PAK1 drugs which would be useful for the treatment of these PAK1-dependent cancers or tumors. Of the anti-PAK1 drugs/ingredients that have been identified or developed for the treatment of NF1-dependent Ser/Thr kinase (Hirokawa et al., 2004). Several years ago, NF1-deficient tumors were shown to require PAK1 for their growth in vivo, and more recently it was found that NF2-deficient tumors also require the same kinase for their growth in vitro (Hirokawa et al., 2004). However, so far no effective NF therapeutic is available on the market. Thus, we have been developing a series of anti-PAK1 drugs which would be useful for the treatment of these PAK1-dependent cancers or tumors. Of the anti-PAK1 drugs/ingredients that have been identified or developed for the treatment of NF1...
and NF2 tumors, a natural ring peptide FK228 appears to be the most potent both in vitro and in vivo. The IC$_{50}$ for NF tumor cells is around 5 pM in vitro, and causes the complete regression of NF1-deficient MPNST xenograft in mice (Hirokawa et al., 2005b). Its direct target is an HDAC (histone deacetylase), and it activates a specific set of tumor suppressor genes such as p21 (a CDK inhibitor) and RAP1a (a RAS antagonist), which eventually block both up-stream and down-stream of PAK1 (Hirokawa et al., 2005a). Unfortunately, FK228 is still in clinical trials (phase 2) for cancers, but not for NF, and it would take several more years for this powerful drug to enter NF trials, and eventually to give any benefit to NF patients.

So we have recently started developing anti-PAK1 ingredients from natural products which are inexpensively available on the market, hoping to give the immediate benefit to NF patients. The first natural anti-PAK1 ingredient(s) was found in an ethanol extract of Chinese (Sichuan) pepper which selectively blocks PAK1 activation, but not another kinase called AKT (Hirokawa et al., 2006). This extract suppresses the growth of NF1-deficient cancer xenografts in mice by 50%. More recently we found there was a much more potent natural anti-NF therapeutic called ‘Bio 30’. It is a water-miscible CAPE-rich extract of NZ (New Zealand) propolis. This study demonstrates that Bio 30 suppressed completely the growth of both NF1 and NF2 tumor xenografts in mice, suggesting the possibility that Bio 30 and other CAPE-rich propolis might serve as the first effective and very safe NF therapeutic inexpensively available on the market.

MATERIALS AND METHODS

Tumor xenografts in mice. 6-week-old female nu/nu mice (from Charles River or NCI) received 5 million MPNST (S-462) cells (Hirokawa et al., 2005b, 2006) or 2–5 million NF2-deficient Schwannoma (HEI-193) cells (Prabhakar et al., 2007; Lepont et al., 2008) of human origin in 0.2 mL of 50% Matrigel per mouse subcutaneously in the flank or thigh. When the average size of the tumors reached around 5 mm diameter (length or width), groups of 5–7 mice were treated with either Bio 30 (100–300 mg/kg) alone or CAPE 60 (Bio 30 plus extra 5 mg/kg CAPE) i.p., twice a week, while the control mice were treated with the vehicle (11% propylene glycol and 26% DMSO in PBS). The size of each tumor (both the original and metastasized) was measured twice a week by calliper. None of these treatments caused any adverse effect on the mice.

Cell culture. 10$^3$ cells of MPNST or Schwannoma cell lines were seeded per well, and cultured for 3–6 days, in the presence or absence of Bio 30, CAPE or ARC at various concentrations and the growth was monitored by either counting viable cells with a hemocytometer or MTT method (measuring the optical density at 550 nm) as described previously (Mosmann, 1983; Hirokawa et al., 2006).

Polyphenol content analysis of Bio 30. The Bio 30 (alcohol-free liquid) sample was extracted by ethyl acetate and subjected to liquid chromatography to analyse its major polyphenols including CAPE by the tandem mass spectrometric method described previously (Celli et al., 2004).

RESULTS AND DISCUSSION

Effect of Bio 30 on the growth of NF1 and NF2 tumor cells in vitro

Since it was found that Bio 30 (Manuka Health, NZ) was more potent than the Chinese pepper extract (Hirokawa et al., 2006) in inhibiting the growth of PAK1-dependent pancreatic and breast cancer cell lines both in vitro and in vivo (Y. Hirokawa and H. Maruta, unpublished observation), its effect on NF tumor cell lines was examined in vitro to begin with. The IC$_{50}$ of Bio 30 for NF2 tumor (HEI-193) and NF1 cancer (MPNST/S-462) cells turned out to be around 1.5 μg/mL and 8 μg/mL, respectively (see Fig. 1).

Effects of Bio 30 on the growth (or metastasis) of NF tumor xenografts in mice

Effect on the growth of NF1-deficient MPNST. Bio 30 (100 mg/kg, i.p., twice a week) suppressed completely

Figure 1. Bio 30 inhibits the growth of NF tumor cells MPNST (A) and Schwannoma (B) cells cultured for 6 days in the presence or absence of Bio 30 at the concentrations indicated as described under Materials and Methods.

Figure 2. Bio 30 suppresses the growth of MPNST in vivo in nude mice bearing MPNST on the flank were treated with Bio 30 (100 mg/kg), i.p., twice a week during days 19–100, as described under Materials and Methods. Each group consisted of five mice.

Figure 3. Bio 30 alone or its combination CAPE 60 blocks metastasis of MPNST in nude mice bearing MPNST on the thigh treated with either Bio 30 (100 mg/kg) alone or CAPE 60, i.p., twice a week during days 27–63, as described under Materials and Methods. Each group consisted of six mice. While all the control mice continued carrying tumors, the Bio 30 alone-treated mice lost two original tumors, and the CAPE-treated mice lost four original tumors by day 63. The number of metastasized tumors represents the total number of those in each group, and not the average per mouse of each group.

Effects on the highly metastatic NF1-deficient MPNST. It was found that the MPNST became highly metastatic and grew much more slowly if MPNST cells were inoculated in the thigh of a back leg, instead of the flank. This provided a good opportunity to examine the antimitastatic effect of Bio 30 (100 mg/kg) alone or its combination with an extra CAPE (5 mg/kg) called ‘CAPE 60’ (containing 60 mg of CAPE, instead of 12 mg of CAPE, per g of Bio 30 extract) on the MPNST. At around 6 weeks, the metastasis of tumors began in the control mice (Fig. 3). However, in the Bio 30 (alone)-treated mice, the total number of metastasized tumors was reduced significantly. Furthermore, extra CAPE significantly delayed the onset of metastasis and enhanced the antimitastatic effect of Bio 30. In addition, Bio 30 alone or its combination with extra CAPE (CAPE 60) caused the regression of MPNST: while all the control mice bore tumors, a third of Bio 30-treated mice and two thirds of CAPE 60-treated mice lost the tumors completely over 10 weeks. PAK1 is known to be essential for anchorage-independent growth, metastasis...
and angiogenesis of cancers in general (Kiosses et al., 2002; Maruta and Ohta, 2008). These observations together strongly suggest that CAPE is the limiting antitumor ingredient of Bio 30, and extra CAPE would boost both its antimetastatic and antimitotic (or/and antiangiogenic) effects on the MPNST. The richer in CAPE, the more therapeutic a propolis might be (on NF tumors).

**Effect on the growth of NF2-deficient Schwannoma**

Bio 30 alone (100 mg/kg, i.p., twice week) caused an almost complete regression of the fast-growing human NF2-deficient Schwannoma (HEI-193) xenograft in mice over 30 days (see Fig. 4A). This regression occurred only when the drug treatment started at an early stage of tumor growth (with the average volume of tumors being around 150 mm³).

However, if the treatment started after the tumor size reached around 400 mm³, the therapeutic effect of Bio 30 was hardly observed at this dose (data not shown). With the tripled dose (300 mg/kg), even if the drug treatment started when the tumor size reached over 600 mm³, Bio 30 alone could suppress the growth of Schwannoma almost completely for 30 days (see Fig. 4B). This size of NF2 tumors in mice (weighing around 20 g) is equivalent to that of a fairly large NF2 tumor (over 1.5 kg) for people (weighing around 50 kg). These observations seem to parallel the clinical situation in that the earlier the treatment begins, the better the chance of complete tumor regression.

**CAPE alone versus Bio 30**

Propolis such as Bio 30 contains plenty of lipids which solubilize CAPE and a few other anticancer polyphenols such as galangin, chrysin and apigenin (see Table 1). Furthermore, CAPE appears to work synergistically with these other polyphenols in Bio 30 to suppress the growth of these NF tumor cells at least in vitro. For instance, as mentioned before, the IC₅₀ of Bio 30 for the Schwannoma cell line is around 1.5 μg/mL. Since the CAPE content of this propolis extract is only 1.2% (12 mg/g of extract), the contribution of CAPE alone to 1.5 μg/mL of Bio 30 is only around 18 ng/mL, that is to say, around 60 nM. The IC₅₀ of CAPE alone for the same cells is as high as about 36 μM (see Fig. 5) which

---

**Table 1. Major polyphenol content of Bio 30**

<table>
<thead>
<tr>
<th>Compound</th>
<th>mg/g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pinocembrin</td>
<td>110</td>
</tr>
<tr>
<td>Galangin*</td>
<td>60</td>
</tr>
<tr>
<td>Chrysin*</td>
<td>30</td>
</tr>
<tr>
<td>CAPE*</td>
<td>12</td>
</tr>
<tr>
<td>CA*</td>
<td>12</td>
</tr>
<tr>
<td>Apigenin*</td>
<td>12</td>
</tr>
</tbody>
</table>

The ethyl acetate extract of Bio 30 was analysed as described under Materials and Methods. The source of Bio 30 was Manuka Health, Auckland, New Zealand.

*Anticancer compounds.
is around 600 times higher than 60 nM. Since the IC\textsubscript{50} of a few other anticancer ingredients such as galangin, chrysin and apigenin is known to be around a similar range (10–40 \textmu M) for various cancer cells (Murray et al., 2006; Maruta and Ohta, 2008), it is most likely that CAPE acts synergistically (rather than simply additively) with these anticancer ingredients in Bio 30. In other words, the water-miscible Bio 30 would be far more effective than the water-insoluble CAPE alone for the treatment of NF tumors. Besides propolis in general is known to have an additional (indirect) anticancer function that boosts the immune system, in particular the lytic action of natural killers against tumor cells, and the antibody production (Sforcin, 2007).

**Bio 30 trials**

Since Bio 30 is a very safe healthcare food supplement, a trial is being conducted of Bio 30 (daily oral treatment with a dose of 25 mg/kg) for, so far, around 70 patients of body weight over 25 kg (or over 10 years old) who are suffering from either NF or formidable cancers such as melanoma and pancreatic cancers in which RAS is mutated and therefore PAK1 is abnormally activated. Its daily cost per person (adult) is only a dollar. The only minor potential problem with CAPE-based propolis such as Bio 30 is that less than 5% of people are allergic to CAPE. In our Bio 30 trial, so far only one person has shown an allergic skin rash, and switched to ARC-based Brazilian green propolis which does not cause any allergy but costs around 10 times as much as Bio 30.

Although our trial is still at a very early stage (less than 12 months for NF1 patients and 6 months for NF2 and a few other cancer patients), so far the majority of these patients showed a positive outcome from Bio 30, namely no further growth of their tumors. It is our hope that this work will set the stage, a milestone for much more sophisticated and comprehensive clinical studies in the future for testing the effect of Bio-30 not only on the growth of NF tumors and PAK1-dependent formidable cancers such as pancreatic cancers, melanomas and MM (multiple myeloma), but also several other PAK1-dependent diseases such as AIDS (HIV-infection) and Fragile X mental retardation syndrome (Nguyen et al., 2006; Hayashi et al., 2007; Porchia et al., 2007; Zhang et al., 2007; Maruta and Ohta, 2008).

**Acknowledgement**

This work was supported in part by funds from DFG (Deutsche Forschungsgemeinschaft) to HM, NF CURE Japan to VM and SMM, and US DOD (No. N000145) to VM, and The Peterson Foundation in Philadelphia to SMM. Support was also received from the NIH Bioceramics Research Center at MB (P41 RR00195). Bio 30 was kindly provided by Manuka Health, New Zealand.

**REFERENCES**


